Duration of tenofovir disoproxil fumarate treatment and a rapid eGFR decline in a retrospective cohort of people living with HIV infection
Medicine in Drug Discovery · 2026-08 · 31 · 100262
DOI: 10.1016/j.medidd.2026.100262 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicine in Drug Discovery, 2026-08. Verfasst von Chutatip Limkunakul und 5 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Srinakharinwirot University.
Abstract (Originalsprache)
Background
Tenofovir disoproxil fumarate (TDF) is one of the first-line antiretroviral therapies in patients with HIV infection. It may be associated with renal impairment. This study aimed to evaluate risk factors for a rapid decline in estimated glomerular filtration rate (eGFR) in patients with HIV infection treated with a TDF-based regimen.
Methods
This was a retrospective cohort study conducted in adult patients with HIV infection who were aged 18 years or older, had a baseline eGFR of 90 ml/min/1.73m 2 , and were treated at an HIV clinic with TDF. The primary outcome of this study was a decline in eGFR of 5 or more ml/min/1.73m 2 with stable or deteriorating eGFR in the following year. Predictors of rapid eGFR decline were calculated by logistic regression analysis.
Results
A total of 533 patients with HIV infection met the study criteria. Of those, 174 patients (32.65%) experienced an eGFR decline of 5 ml/min/1.73m 2 or more after treatment with TDF. The average follow-up time was 7.94 years (SD 1.80). Four factors were identified in the predictive model for a decline in eGFR of 5 or more ml/min/1.73m 2 , including age, hepatitis B virus infection, urine albumin-to-creatinine ratio, and duration of TDF treatment. Only duration of TDF treatment was independently associated with a decline in eGFR of 5 or more ml/min/1.73m 2 , with an adjusted odds ratio of 1.188 (95% confidence interval: 1.063–1.328).
Conclusion
This long-term cohort study of patients with HIV infection treated with TDF showed that duration of TDF treatment may be associated with a rapid decline in eGFR. Annual monitoring of eGFR is warranted.
Förderung
- Srinakharinwirot University
Zitieren
APA
Limkunakul, C., Srinithiwat, P., Thienmanee, M., Vatunyootawewat, P., Phuthomdee, S., & Sawanyawisuth, K. (2026). Duration of tenofovir disoproxil fumarate treatment and a rapid eGFR decline in a retrospective cohort of people living with HIV infection. Medicine in Drug Discovery, 31, 100262. https://doi.org/10.1016/j.medidd.2026.100262
Vancouver
Limkunakul C, Srinithiwat P, Thienmanee M, Vatunyootawewat P, Phuthomdee S, Sawanyawisuth K. Duration of tenofovir disoproxil fumarate treatment and a rapid eGFR decline in a retrospective cohort of people living with HIV infection. Medicine in Drug Discovery. 2026;31:100262. doi:10.1016/j.medidd.2026.100262
BibTeX
@article{Limkunakul2026,
author = {Limkunakul, Chutatip and Srinithiwat, Palakorn and Thienmanee, Madhuros and Vatunyootawewat, Peerapon and Phuthomdee, Sadiporn and Sawanyawisuth, Kittisak},
title = {Duration of tenofovir disoproxil fumarate treatment and a rapid eGFR decline in a retrospective cohort of people living with HIV infection},
journal = {Medicine in Drug Discovery},
year = {2026},
volume = {31},
pages = {100262},
doi = {10.1016/j.medidd.2026.100262}
}
EUVIMED